Richard T Pomerantz
Overview
Explore the profile of Richard T Pomerantz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
1351
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ito F, Li Z, Minakhin L, Chandramouly G, Tyagi M, Betsch R, et al.
Nat Commun
. 2024 Aug;
15(1):7003.
PMID: 39143110
DNA polymerase theta (Polθ) is a DNA helicase-polymerase protein that facilitates DNA repair and is synthetic lethal with homology-directed repair (HDR) factors. Thus, Polθ is a promising precision oncology drug-target...
2.
Vekariya U, Minakhin L, Chandramouly G, Tyagi M, Kent T, Sullivan-Reed K, et al.
Nat Commun
. 2024 Jul;
15(1):5822.
PMID: 38987289
DNA polymerase theta (Polθ)-mediated end-joining (TMEJ) repairs DNA double-strand breaks and confers resistance to genotoxic agents. How Polθ is regulated at the molecular level to exert TMEJ remains poorly characterized....
3.
Ito F, Li Z, Minakhin L, Khant H, Pomerantz R, Chen X
bioRxiv
. 2024 Jun;
PMID: 38895274
DNA double-strand breaks (DSBs) present a critical threat to genomic integrity, often precipitating genomic instability and oncogenesis. Repair of DSBs predominantly occurs through homologous recombination (HR) and non-homologous end joining...
4.
Fried W, Tyagi M, Minakhin L, Chandramouly G, Tredinnick T, Ramanjulu M, et al.
Nat Commun
. 2024 Apr;
15(1):2862.
PMID: 38580648
The DNA damage response (DDR) protein DNA Polymerase θ (Polθ) is synthetic lethal with homologous recombination (HR) factors and is therefore a promising drug target in BRCA1/2 mutant cancers. We...
5.
Calbert M, Chandramouly G, Adams C, Saez-Ayala M, Kent T, Tyagi M, et al.
Mol Cancer Ther
. 2023 Dec;
23(5):683-699.
PMID: 38064712
Anticancer nucleosides are effective against solid tumors and hematologic malignancies, but typically are prone to nucleoside metabolism resistance mechanisms. Using a nucleoside-specific multiplexed high-throughput screening approach, we discovered 4'-ethynyl-2'-deoxycytidine (EdC)...
6.
Krais J, Glass D, Chudoba I, Wang Y, Feng W, Simpson D, et al.
Nat Commun
. 2023 Nov;
14(1):7714.
PMID: 38001070
Homologous recombination (HR)-deficiency induces a dependency on DNA polymerase theta (Polθ/Polq)-mediated end joining, and Polθ inhibitors (Polθi) are in development for cancer therapy. BRCA1 and BRCA2 deficient cells are thought...
7.
Mensah I, Norvil A, He M, Lendy E, Hjortland N, Tan H, et al.
J Biol Chem
. 2023 Sep;
299(10):105257.
PMID: 37716702
RNA methylation is a ubiquitous post-transcriptional modification found in diverse RNA classes and is a critical regulator of gene expression. In this study, we used Zika virus RNA methyltransferase (MTase)...
8.
Demidova E, Serebriiskii I, Vlasenkova R, Kelow S, Andrake M, Hartman T, et al.
BMC Genomics
. 2023 Jul;
24(1):388.
PMID: 37430226
No abstract available.
9.
Tredinnick T, Kent T, Minakhin L, Li Z, Madzo J, Chen X, et al.
RNA
. 2023 Apr;
29(8):1288-1300.
PMID: 37105714
Synthetic RNA oligonucleotides composed of canonical and modified ribonucleotides are highly effective for RNA antisense therapeutics and RNA-based genome engineering applications utilizing CRISPR-Cas9. Yet, synthesis of synthetic RNA using phosphoramidite...
10.
Demidova E, Serebriiskii I, Vlasenkova R, Kelow S, Andrake M, Hartman T, et al.
BMC Genomics
. 2023 Apr;
24(1):212.
PMID: 37095444
Background: Early-onset renal cell carcinoma (eoRCC) is typically associated with pathogenic germline variants (PGVs) in RCC familial syndrome genes. However, most eoRCC patients lack PGVs in familial RCC genes and...